



- Rolapitant is a highly selective neurokinin 1 receptor (NK1R) antagonist with a half life of 180 hrs.
- Prevents delayed chemotherapy-induced nausea and vomiting (CINV).
- Approved by FDA in September 2015.
- In 2018, FDA posted a warning regarding the risk of anaphylaxis.



TESARO®

A GSK company

Duffy, *Pharmacol. Biochem. Behav.* **2012**, 102, 95
 O'Donnel, *J. Med. Chem.* **2017**, 60, 6480
 Patents: WO2010028232A1 & US7049320B2



